Continuous glucose monitoring may lower mortality risk in diabetic patients on insulin
In 27,870 matched patients, CGM users had 44% lower one-year death risk and fewer heart failure hospitalisations, researchers said.
4 Articles
4 Articles
Continuous glucose monitors show strong survival benefits for type 2 diabetes patients
People with type 2 diabetes (T2D) on basal insulin, starting continuous glucose monitoring (CGM) had a 44% lower risk of dying from any cause after one year compared with those who did not use CGM, with the risk being 35% lower after two years, according to an analysis of patient data being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).
Continuous glucose monitoring may lower mortality risk in diabetic patients on insulin
People with type 2 diabetes (T2D) who began using continuous glucose monitoring (CGM) while receiving basal insulin had a 44% lower risk of dying from any cause after one year than those who did not use CGM, according to an analysis of patient data being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2. After two years, their risk was 35% lower.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium





